In the prospective, observational, multicenter, real-world POLARIS study (palbociclib in hormone receptor-positive advanced breast cancer: a prospective multicenter non-interventional study), a primary aim was to assess PROs among patients treated with palbociclib plus ET in routine clinical practice.8 The gene discussed is NR4A1; the disease is breast carcinoma.